Literature DB >> 837632

Studies on digitalis. VIII. Digitoxin metabolism on a maintenance regimen and after a single dose.

L Storstein.   

Abstract

The metabolic pattern of cardioactive and inactive conjugated metabolites of digitoxin on maintenance (9 patients) and after a single 0.6-mg dose (5 patients) was studied in patients with normal renal and hepatic function. Serum samples were obtained 24 hr after the last dose, and urine was collected over 24 hr. The extent of conjugation to glucuronic and sulfuric acid was 35.0% (SD, 17.4) in whole serum and 31.6% (SD, 19.3) in urine samples. Unchanged digitoxin was the main cardioactive substance found both in serum and in urine (89.7% and 87.0%) in the steady-state group. All known cardioactive metabolites were present; digoxin represented less than 1%. All active metabolites were conjugated to glucuronic/sulfuric acid. Serum and urine patterns of metabolites were quite similar, Hydrolysis and conjugation appeared to be more important pathways than hydroxylation. Unchanged digitoxin was the most important cardioactive substance in serum and urine (80.4% and 56.5%) in the single-dose group. Digoxin was the main cardioactive metabolite (12.5% in serum and 25.5% in urine). All active metabolites were conjugated. Hydroxylation, hydrolysis, and conjugation seemed to be equally important. The most important differences between the steady-state and single-dose groups were that in the steady-state group there was significantly more unchanged digitoxin, far less digoxin, and less hydroxylated metabolities than in the single-dose group. Caution is thus necessary when interpreting single-dose data for a drug that is used for maintenance.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 837632     DOI: 10.1002/cpt1977212125

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Clinical pharmacokinetics of digitoxin.

Authors:  D Perrier; M Mayersohn; F I Marcus
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

2.  Pharmacokinetics and bioavailability of digitoxin by a specific assay.

Authors:  R T MacFarland; F I Marcus; P E Fenster; P E Graves; D Perrier
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

4.  Reductive inactivation of digitoxin by Eubacterium lentum cultures.

Authors:  A Chandrasekaran; L W Robertson; R H Reuning
Journal:  Appl Environ Microbiol       Date:  1987-04       Impact factor: 4.792

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.